Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Phase II Study of TAS5315 in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate
jRCT2080223962Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TAS5315 in rheumatoid arthritis (RA) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Started Jul 2018; status: completed.
02
Drugs
TAS5315
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080223962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223962.